Full Press Release Details
Menlo Park, California, November 04, 2016. 3-V Biosciences, Inc., a clinical-stage pharmaceutical company developing therapeutics for liver diseases, including non-alcoholic steatohepatitis (NASH), and oncology announced today that it has been selected for a Presidential Poster of Distinction at the American Association for the Study of Liver Diseases (The Liver Meeting®) being held November 11 th -15 th in Boston, Massachusetts.
Title: Pharmacological inhibition of FASN Prevents High Fat Diet Induced Liver Damage in Mice and Significantly Reduces de novo Lipogenesis in Humans Session ID: Poster session III Session Title: Steatohepatitis: Experimental II Session Date: Sunday, November 13, 2016 Session Time: 12:30 – 2:00PM local time Location: Hall C Abstract Number: 1547
3-V Biosciences, Inc. is a clinical-stage pharmaceutical company developing novel therapeutics in liver diseases and oncology based on expertise in lipid biology. The company’s lead product candidate is a first-in-class inhibitor of fatty acid synthase (FASN) currently being evaluated in a Phase 1 clinical trial. Lipids are integral to cellular metabolism, cellular signaling and cellular structure and the emerging understanding of lipid biology opens up promising new areas for drug development. The company is located in Menlo Park, California.
For additional information on 3-V Biosciences, please visit www.3vbio.com.com.